Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: GlaxoSmithKline Research & Development Ltd
Woman and Man Max 99 years
GlaxoSmithKline Research & Development Ltd
Update Il y a 5 ans
An open-label, non-randomized, pharmacokinetic and safety study of repeat doses of fluticasone furoate and GW642444M combination in healthy subjects and in subjects with mild, moderate or severe hepatic impairment
To investigate the effect of varying degrees of hepatic impairment on the pharmacokinetics of FF and GW642444 following repeat administration of FF 200mcg/GW642444M 25mcg via a novel Dry Powder Inhale...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
GlaxoSmithKline Research & Development Ltd
Update Il y a 5 ans
A 24-Week Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder and the Individual Components Delivered Once Daily (AM) Via a Novel Dry Powder Inhaler Compared with Placebo in Subjects with Chronic Obstructive Pulmonary Disease (COPD)
The primary objective of the study is to evaluate the efficacy and safety of FF/GW642444 Inhalation Powder 100/25mcg QD, FF/GW642444 Inhalation Powder 200/25mcg QD, FF Inhalation Powder 100mcg QD, FF ...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
GlaxoSmithKline Research & Development Ltd
Update Il y a 5 ans
A Randomized, Double-blind, Double-Dummy, Multicenter, Non-inferiority Phase III Study to Assess the Safety and Efficacy of Topical 1% SB-275833 Ointment, Applied Twice Daily, versus Oral Cephalexin, 500mg in Adults, or 12.5mg/kg (250mg/5mL) in Children, Twice Daily, in the Treatment of Secondarily-Infected Dermatoses
The primary objective of this study is to demonstrate that topical 1% SB-275833 ointment, applied twice daily for 5 days, is at least as effective clinically as oral cephalexin, 500mg in adults, or 12...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
GlaxoSmithKline Research & Development Ltd
Update Il y a 5 ans
Assessing the Potential Ability of GSK239512 to Remyelinate Brain Lesions in Relapsing Remitting Multiple Sclerosis
Estimation of the effects of GSK239512 on lesion remyelination in subjects with Relapsing Remitting Multiple Sclerosis on stable treatment with Avonex [interferon-beta1a] or Copaxone [glatiramer ace...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
GlaxoSmithKline Research & Development Ltd
Update Il y a 5 ans
A Phase III, 18 Month, Multicenter, Randomized, Double-Blind, Active-Controlled Clinical Trial to Compare Rosiglitazone versus Glipizide on the Progression of Atherosclerosis in Subjects with Type 2 Diabetes Mellitus and Cardiovascular Disease
To compare RSG versus GLP on the progression of atherosclerosis as measured by IVUS-derived change in percent atheroma volume from baseline to 18 months in non-intervened coronary arteries of subjects...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
GlaxoSmithKline Research & Development Ltd
Update Il y a 5 ans
A Phase II Study of Lapatinib plus Topotecan or Lapatinib plus Capecitabine in the Treatment of Recurrent Brain Metastases from ErbB2-Positive Breast Cancer Following Cranial Radiotherapy
In each of the two study arms (lapatinib plus topotecan or lapatinib plus capecitabine), the primary objective is to determine the CNS objective response rates in subjects with progressive brain metas...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
GlaxoSmithKline Research & Development Ltd
Update Il y a 5 ans
A multicentre, randomised, double-blind, placebo-controlled, parallel group, dose ranging study to determine the effect of mepolizumab on exacerbation rates in subjects with severe uncontrolled refractory asthma
To evaluate the dose response, based on efficacy and safety of three doses of mepolizumab (75 mg, 250 mg and 750 mg) over a 52-week treatment period in adult and adolescent subjects with severe uncont...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
GlaxoSmithKline Research & Development Ltd
Update Il y a 5 ans
Study HZC111348, a repeat-dose study of GW685698/GW642444 Inhalation Powder versus placebo in the treatment of Chronic Obstructive Pulmonary Disease (COPD)
To evaluate the safety and tolerability of GW685698 /GW642444 administered once-daily for 4 weeks in subjects with COPD.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
GlaxoSmithKline Research & Development Ltd
Update Il y a 5 ans
A Study to Evaluate the Efficacy and Safety of Losmapimod in Subjects with COPD who Frequently Exacerbate
To evaluate the rate of COPD exacerbations in losmapimod compared to placebo treated subjects.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
GlaxoSmithKline Research & Development Ltd
Update Il y a 5 ans
A Real-World Use Study of Safety Syringe for the Administration of Mepolizumab in Severe Asthma
To assess the use of the combination product, mepolizumab liquid drug product in safety syringe for the subcutaneous self-administration of mepolizumab by subjects with severe eosinophilic asthma
Country
None
organs
None
Specialty
None
unknown
More information
Previous
5
6
7
8
9
10
11
12
13
14
Next